相关实验视频
Updated: Sep 13, 2025

Engineering Antiviral Agents via Surface Plasmon Resonance
Published on: June 14, 2022
准SARS-CoV-2主要蛋白酶:一个药和分子建模方法
Nitchakan Darai1, Piyatida Pojtanadithee2, Kamonpan Sanachai3
1Center of Excellence in Biocatalyst and Sustainable Biotechnology, Department of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok, 10330, Thailand.
研究人员通过计算选化合物确定了潜在的COVID-19治疗方法. E912-0363已成为SARS-CoV-2主要蛋白酶 (Mpro) 的有前途的抑制剂,显示出治疗潜力.
科学领域:
- 计算机化药物发现.
- 病毒学 病毒学
- 药用化学 医学化学
背景情况:
- 由于COVID-19的流行,需要新的治疗方法.
- SARS-CoV-2 主蛋白酶 (Mpro) 对于病毒复制至关重要,也是关键的药物标.
- 现有的治疗方法,如尼尔马特里尔维尔,突出了对替代抑制剂的需求.
研究的目的:
- 使用计算方法识别SARS-CoV-2 Mpro的新型抑制剂.
- 评估潜在候选药物的结合亲和力和稳定性.
- 发现替代性或补充性治疗方法的nirmatrelvir.
主要方法:
- 从ChemDiv数据库中对89,200种化合物的虚拟选.
- 药模拟和类似药物的属性预测.
- 分子对接,分子动力学 (MD) 模拟和结合自由能计算 (MM/GBSA).
主要成果:
- 确定了E912-0363和G740-1003作为有前途的Mpro抑制剂,其亲和力与nirmatrelvir.vir相似.
- 扩展500纳米的MD模拟证实了E912-0363的稳定性和强大的Mpro抑制.
- 计算选成功地缩小了进一步药物开发的候选人.
结论:
- E912-0363是一种非常有前途的SARS-CoV-2 Mpro抑制剂.
- 这种化合物显示出作为COVID-19的补充或替代治疗剂的潜力.
- 综合计算方法对于识别新型抗病毒药物候选者是有效的.
更多相关视频
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
07:53A Fluorogenic Peptide Cleavage Assay to Screen for Proteolytic Activity: Applications for coronavirus spike protein activation
Published on: January 9, 2019
相关概念视频
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Molecular Models
Conjugated Proteins
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...